Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-24T14:43:06.871Z Has data issue: false hasContentIssue false
  • English
  • Français

Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study

Published online by Cambridge University Press:  26 July 2016

V Noronha ,
C Goswami ,
S Patil ,
A Joshi ,
V M Patil ,
V Murthy ,
S Arya ,
S Juvekar ,
S Goud  and
K Prabhash
V Noronha
Affiliation:
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
C Goswami
Affiliation:
Department of Medical Oncology, B. P. Poddar Hospital and Medical Research Ltd, Kolkata, India
S Patil
Affiliation:
Department of Medical Oncology, HCG Hospital, Bengaluru, Karnataka, India
A Joshi
Affiliation:
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
V M Patil
Affiliation:
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
V Murthy
Affiliation:
Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India
S Arya
Affiliation:
Department of Radiodiagnosis, Tata Memorial Hospital, Parel, Mumbai, India
S Juvekar
Affiliation:
Department of Radiodiagnosis, Tata Memorial Hospital, Parel, Mumbai, India
S Goud
Affiliation:
Department of Medical Oncology, HCG Hospital, Bengaluru, Karnataka, India
K Prabhash*
Affiliation:
Department of Medical Oncology, HCG Hospital, Bengaluru, Karnataka, India
*
Address for correspondence: Dr K Prabhash, Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai 400012, Maharashtra, India E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Docetaxel, cisplatin plus 5-fluorouracil is an efficacious induction regimen but is more toxic than cisplatin plus 5-fluorouracil. This study aimed to determine whether docetaxel and cisplatin without 5-fluorouracil maintains efficacy while decreasing toxicity.

Methods:

A multicenter non-comparative pilot study of locally advanced squamous cell carcinoma of the head and neck was performed. Patients received primary therapy comprising three cycles of 75 mg/m2 docetaxel and 75 mg/m2 cisplatin followed by concurrent chemoradiotherapy. The primary endpoint was the response rate to the docetaxel and cisplatin induction regimen.

Results:

A total of 26 patients were enrolled: of these, 23 (88.5 per cent) received all three docetaxel and cisplatin cycles. Common grade 3–4 adverse events were febrile neutropenia (19.2 per cent of patients), diarrhoea (19.2 per cent) and non-neutropenic infection (15.4 per cent). The overall response rate to docetaxel and cisplatin induction chemotherapy was 65.4 per cent. A total of 23 patients (88.5 per cent) subsequently received chemoradiotherapy with a median radiotherapy dose of 70 Gy. The response rate to chemoradiotherapy was 73 per cent. At a median follow up of 44 months, the 3-year progression-free survival and overall survival rates were 62 per cent and 69 per cent, respectively.

Conclusion:

Docetaxel and cisplatin induction chemotherapy is a feasible induction regimen with comparable efficacy to docetaxel, cisplatin and 5-fluorouracil induction chemotherapy.

Keywords

Induction ChemotherapyHead and Neck NeoplasmsTaxoidsNeoadjuvant Therapy
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 130 , Issue 9 , September 2016 , pp. 833 - 842
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Cohen, EE, Karrison, TG, Kocherginsky, M, Mueller, J, Egan, R, Huang, CH et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:2735–43CrossRefGoogle ScholarPubMed
2 Haddad, R, O'Neill, A, Rabinowits, G, Tishler, R, Khuri, F, Adkins, D et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013;14:257–64Google Scholar
3 Hitt, R, Grau, JJ, López-Pousa, A, Berrocal, A, Garcia-Giron, C, Irigoyen, A et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014;25:216–25Google Scholar
4 Vermorken, JB, Remenar, E, van Herpen, C, Gorlia, T, Mesia, R, Desgardin, M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–704Google Scholar
5 Posner, MR, Hershock, DM, Blajman, CR, Mickiewicz, E, Winquist, E, Gorbounova, V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–15CrossRefGoogle ScholarPubMed
6 Brockstein, B, Haraf, D J, Rademaker, AW, Kies, MS, Stenson, KM, Rosen, F et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15:1179–86Google Scholar
7 Cockcroft, DW, Gault, MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41 Google Scholar
8 Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47Google Scholar
9 National Cancer Institute, 2015. NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4: core terminology. In: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf [28 August 2015]Google Scholar
10 Pointreau, Y, Garaud, P, Chapet, S, Sire, C, Tuchais, C, Tortochaux, J et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498–506 CrossRefGoogle ScholarPubMed
11 Fonseca, E, Grau, JJ, Sastre, J, Garcia-Gomez, JM, Rueda, A, Pastor, M et al. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer 2005;41:1254–60CrossRefGoogle ScholarPubMed
12 Patil, V, Noronha, V, Joshi, A, Muddu Krishna, V, Juvekar, S, Pantvaidya, G et al. Is there a limitation of RECIST criteria in prediction of pathological response, in head and neck cancers, to postinduction chemotherapy. ISRN Oncol 2013;2013:259154 Google Scholar
13 Corry, J, Peters, L, Kleid, S, Rischin, D. Larynx preservation for patients with locally advanced laryngeal cancer. J Clin Oncol 2013;31:840–4Google Scholar
14 National Comprehensive Cancer Network. Available online at: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf [29 August 2015]Google Scholar
15 Richard, JM, Sancho-Garnier, H, Pessey, JJ, Luboinski, B, Lefebvre, JL, Dehesdin, D et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998;34:224–8Google Scholar
16 Lefebvre, JL, Chevalier, D, Luboinski, B, Kirkpatrick, A, Collette, L, Sahmoud, T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890–9CrossRefGoogle ScholarPubMed
17 American Society of Clinical Oncology, Pfister, DG, Laurie, SA, Weinstein, GS, Mendenhall, WM, Adelstein, DJ et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693–704CrossRefGoogle Scholar
18 Forastiere, AA, Goepfert, H, Maor, M, Pajak, TF, Weber, R, Morrison, W et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–8Google Scholar
19 Calvert, AH, Newell, DR, Gumbrell, LA, O'Reilly, S, Burnell, M, Boxall, FE et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56Google Scholar
20 Dandekar, M, D'Cruz, A. Organ preservation strategies: review of literature and their applicability in developing nations. South Asian J Cancer 2014;3:147–50Google Scholar